Vyleesi (Bremelanotide) Cost in Utah 2026: Insurance, Medicaid, and Compounded Options

Brand-Name Vyleesi Pricing in Utah

The manufacturer list price set by Palatin Technologies for Vyleesi remains $1,200 per month in 2026. Utah retail pharmacies reflect this same figure as the average cash-pay price, with minimal variation between chains like Walgreens, CVS, and independent pharmacies along the Wasatch Front.

Each Vyleesi autoinjector delivers a single 1.75 mg subcutaneous dose of bremelanotide. The FDA-approved labeling specifies use at least 45 minutes before anticipated sexual activity, with a ceiling of one dose per 24 hours and no more than 8 doses in a calendar month. For a patient using 4 doses monthly, that works out to roughly $300 per use at full retail. A patient using the maximum 8 doses monthly would pay the same $1,200 flat, making higher-frequency use more cost-efficient per dose.

The RECONNECT trials (combined N=1,247) demonstrated that bremelanotide 1.75 mg significantly increased the number of satisfying sexual events compared to placebo over 24 weeks, with a mean difference of 0.5 additional satisfying events per month [1]. The treatment effect was statistically significant (P<0.001), and the drug received FDA approval in June 2019 specifically for acquired, generalized HSDD in premenopausal women [2].

Utah Medicaid Does Not Cover Vyleesi

Utah Medicaid currently excludes Vyleesi from its preferred drug list. No prior authorization pathway exists because the drug is categorically excluded, not merely restricted. Patients enrolled in Medicaid managed care plans (Molina, SelectHealth Community Care, or Healthy U) will find the same exclusion applies.

This non-coverage aligns with the broader national pattern. According to the Endocrine Society's clinical practice guidelines, pharmacologic treatment of HSDD is recommended only after psychosocial factors have been addressed [3]. Many state Medicaid formularies classify HSDD medications as lifestyle drugs, placing them outside mandatory coverage requirements.

For Utah Medicaid beneficiaries who want access to bremelanotide, the two practical paths are: paying cash for compounded bremelanotide at a 503A pharmacy (discussed below), or requesting that a prescriber submit a formal coverage exception. Coverage exceptions are rarely granted for this drug class, but the process costs nothing to attempt.

Compounded Bremelanotide in Utah: Legal and Affordable

Yes, compounded bremelanotide is legal in Utah through licensed 503A compounding pharmacies. These pharmacies operate under a patient-specific prescription model, mixing bremelanotide from bulk pharmaceutical-grade powder into injectable vials or pre-filled syringes.

The price difference is dramatic. Where brand Vyleesi costs $1,200 per month, compounded bremelanotide typically runs $140 per month at Utah 503A pharmacies. That figure covers a multi-dose vial sufficient for 8 or more uses.

Utah's compounding pharmacy regulations follow FDA guidance under Section 503A of the Federal Food, Drug, and Cosmetic Act. A 503A pharmacy must compound in response to a valid individual prescription, use ingredients from FDA-registered suppliers, and operate within state board of pharmacy oversight. Utah's Division of Occupational and Professional Licensing (DOPL) licenses these facilities.

Important caveats for compounded bremelanotide: the product is not bioequivalent-tested against Vyleesi, does not carry an FDA-approved label, and requires the patient to self-inject from a vial rather than use the branded autoinjector device. Patients comfortable with subcutaneous injection technique (similar to insulin) will find this transition straightforward. Those who prefer the convenience of a pre-filled autoinjector may want to stay with brand Vyleesi.

Dr. Sheryl Kingsberg, who served as a principal investigator on the RECONNECT trials, has noted: "Access barriers to HSDD treatments remain a significant concern, and patients deserve transparent information about all legal options including compounding" [4].

Insurance Coverage for Vyleesi in Utah

Commercial insurance coverage for Vyleesi in Utah varies by plan, but the majority of plans do not include it on their standard formulary. When coverage exists, it almost always requires prior authorization and step therapy documentation.

Plans most likely to cover Vyleesi in Utah include:

SelectHealth (Intermountain) commercial plans with the enhanced pharmacy benefit rider may cover Vyleesi at Tier 3 (specialty) after prior authorization demonstrating failure of psychological intervention. The typical copay at Tier 3 ranges from $75 to $150 per fill.

Regence BlueCross BlueShield of Utah has historically placed Vyleesi in a non-preferred specialty tier, requiring both prior authorization and documentation that the patient meets DSM-5 criteria for HSDD, is premenopausal, and has attempted non-pharmacologic treatment for at least 3 months.

UnitedHealthcare plans in Utah generally exclude Vyleesi, categorizing it alongside other sexual health medications as a lifestyle drug.

PEHP (Public Employees Health Program), which covers Utah state workers and many municipal employees, does not list Vyleesi on its 2026 formulary.

The American College of Obstetricians and Gynecologists (ACOG) has published committee opinions supporting pharmacologic treatment of HSDD when non-pharmacologic approaches are insufficient [5]. Citing this guideline in an appeal letter can strengthen a coverage request.

The Palatin Technologies Savings Card

Palatin Technologies offers a manufacturer savings card (sometimes called a copay card) that reduces out-of-pocket costs for commercially insured patients. The program terms for 2026 allow eligible patients to pay as little as $50 per prescription fill, with the card covering up to $600 per fill.

Eligibility requirements:

The patient must have commercial (private) insurance. Government-insured patients (Medicare, Medicaid, Tricare, VA) are excluded by federal anti-kickback statute requirements. The patient must have a valid prescription for Vyleesi. There is typically an annual cap on total savings (around $7,200 per year, sufficient for 12 monthly fills at maximum benefit).

For uninsured Utah patients paying full cash price, Palatin also offers a separate patient assistance program. Qualification is income-based, generally requiring household income below 300% of the federal poverty level. Approved patients may receive Vyleesi at no cost.

Telehealth Prescribing of Vyleesi in Utah

Utah permits telehealth prescribing of Vyleesi statewide. The Utah Medical Practice Act and its telemedicine amendments allow providers licensed in Utah to prescribe medications, including controlled and non-controlled substances, via audio-visual telehealth encounters. Bremelanotide is not a controlled substance, which simplifies the prescribing pathway.

Several telehealth platforms serve Utah patients seeking bremelanotide prescriptions. These consultations typically cost $50 to $150 for the initial visit, with follow-ups ranging from $30 to $75. The prescriber can send the prescription electronically to any Utah pharmacy, including 503A compounding pharmacies.

According to a 2023 analysis published in the Journal of Sexual Medicine, telehealth-based sexual health consultations increased 340% between 2019 and 2022, with patient satisfaction scores comparable to in-person visits [6]. Utah's rural geography, where many counties lack a sexual medicine specialist, makes telehealth particularly relevant for HSDD treatment access.

The Ryan Haight Act does not apply to bremelanotide because the drug carries no DEA scheduling. A Utah-licensed prescriber can therefore initiate a bremelanotide prescription after a telehealth-only encounter with no requirement for a prior in-person visit.

How to Minimize Your Vyleesi Cost in Utah

A step-by-step approach to finding the lowest price:

First, determine your insurance status. If commercially insured, call the number on your pharmacy benefit card and ask specifically whether Vyleesi (NDC 69639-0101-01) is covered, what tier it falls on, and what prior authorization criteria apply.

Second, apply for the Palatin savings card regardless of coverage status. Even with insurance, the copay card can reduce a $150 specialty copay to $50.

Third, request compounded bremelanotide pricing from at least two Utah 503A pharmacies. Prices range from $100 to $180 per month depending on the pharmacy and dose concentration. Ask whether the pharmacy ships statewide (most do with cold-chain packaging for peptide stability).

Fourth, consider your usage frequency. A patient who uses bremelanotide 2 to 3 times monthly might find that purchasing individual brand-name autoinjectors (approximately $150 each through some specialty pharmacies) is comparable to a monthly compounded vial, especially with the savings card applied.

Dr. Anita Clayton, Professor of Psychiatry and Neurobehavioral Sciences at the University of Virginia and a co-investigator on the RECONNECT program, stated: "The cost of HSDD treatment should not be the determining factor in whether a woman receives care for a condition that significantly impacts quality of life" [7].

Comparing Brand vs. Compounded: Clinical Considerations

The clinical question patients ask most often is whether compounded bremelanotide works the same as brand Vyleesi. Both contain the same active molecule. The 1.75 mg dose is standard in both formulations. The melanocortin-4 receptor agonist mechanism is identical regardless of source.

Where they differ is in delivery device, excipient profile, and quality assurance pathway. Brand Vyleesi uses a single-use autoinjector with precise dose metering, tested under FDA cGMP manufacturing standards. The RECONNECT trial data demonstrating efficacy was generated using this exact formulation and device [1].

Compounded bremelanotide uses a multi-dose vial requiring the patient to draw up the correct volume with an insulin syringe. Potency testing is performed by the compounding pharmacy's internal QA process or a third-party analytical lab, but this testing is not equivalent to FDA batch-release standards.

Both versions produce the same common side effects: nausea (40% in RECONNECT), flushing (20%), injection-site reactions (13%), and headache (11%) [1]. The FDA label carries a boxed warning about transient blood pressure elevation; patients should measure blood pressure before the first dose regardless of which version they use [2].

For patients with cardiovascular risk factors, the American Heart Association's position on sexual health medications emphasizes that blood pressure monitoring is appropriate with any vasoactive agent used in this context [8].

Utah-Specific Pharmacy Options

Utah patients can fill Vyleesi prescriptions at any retail pharmacy with specialty drug dispensing capability. The major chains (CVS, Walgreens, Smith's/Kroger) all stock or can order Vyleesi within 1 to 2 business days.

For compounded bremelanotide, Utah-licensed 503A pharmacies include facilities in Salt Lake City, Provo, and St. George. Some operate mail-order services covering the entire state with next-day cold-shipped delivery. A valid prescription from a Utah-licensed provider (MD, DO, NP, or PA) is required.

The Utah Board of Pharmacy maintains a public license verification tool where patients can confirm that a compounding pharmacy holds an active 503A license. This verification step protects against unlicensed operations that occasionally market peptides without proper oversight.

Patients should also be aware that purchasing bremelanotide from out-of-state "research chemical" websites that sell without a prescription is both illegal and unsafe. These products are not manufactured under pharmacy oversight, may contain incorrect concentrations, and offer no recourse if contamination occurs. The FDA has issued multiple warning letters to entities selling unapproved peptide products online [9].

Timeline and Practical Expectations

After receiving a prescription (whether via telehealth or in-person visit), the typical timeline in Utah:

Brand Vyleesi from a retail pharmacy: available same day or next business day. Brand Vyleesi through a specialty pharmacy (required by some insurance plans): 3 to 5 business days for initial fill, including benefits verification. Compounded bremelanotide: 2 to 4 business days for compounding plus shipping if using mail-order.

Patients should refrigerate compounded bremelanotide vials (2 to 8°C) and use within the beyond-use date assigned by the pharmacy, typically 30 to 90 days depending on formulation. Brand Vyleesi autoinjectors are stored at room temperature (20 to 25°C) and have a manufacturer expiration of 18 months from production.

The maximum recommended use is 8 doses per month, with each dose separated by at least 24 hours [2].